

What is claimed is:

1. Nucleic acid, characterised in that it codes for the non-selective cation channel
 5 OTRPC4 or for a fragment, a functional variant, an allelic variant or a subunit, or
 variants of said nucleic acid on the basis of the degenerative code or a nucleic acid
 which is able to hybridise with said nucleic acid.
2. Nucleic acid according to claim 1, characterised in that it is RNA.
- 10 3. Nucleic acid according to claim 1, characterised in that it is DNA.
4. Nucleic acid according to one of claims 1 or 3, characterised in that it contains 5' or
 3' or 5' and 3' untranslated regions.
- 15 5. Nucleic acid according to one of claims 1 to 4, characterised in that it codes for a
 fragment of the non-selective cation channel OTRPC4.
6. Nucleic acid according to one of claims 1 to 5, characterised in that it codes for a
 20 functional variant of the non-selective cation channel OTRPC4.
7. Nucleic acid according to one of claims 1 to 6, characterised in that it codes for an
 allelic variant of the non-selective cation channel OTRPC4.
- 25 8. Nucleic acid according to one of claims 1 to 7, characterised in that it codes for
 variants of nucleic acid on the basis of the degenerative code.
9. Nucleic acid, characterised in that it is capable of hybridising with a nucleic acid
 according to one of claims 1 to 8 under stringent conditions.
- 30 10. Nucleic acid according to one of claims 1 to 9, characterised in that the said
 non-selective cation channel OTRPC4 is a mammalian cation channel.

11. Nucleic acid according to one of claims 1 to 10, characterised in that the said non-selective cation channel OTRPC4 is murine.
12. Nucleic acid according to one of claims 1 to 11, characterised in that the said non-selective cation channel OTRPC4 is human.
13. Nucleic acid, characterised in that it contains the sequence

CTCTCACCGCCTACTACCAGCCGCTGGAGGGCACAATGGCGGATTCCAGCGAAGGCCC
 10 CCGCGCGGGGCGGGGAGGTGGCTGAGCTCCCCGGGGATGAGAGTGGCACCCCAGG
 TGGGGAGGCTTTTCCTCTCTCCTCCCTGGCCAATCTGTTTGAGGGGGAGGATGGCTCCC
 TTTCCGCCCTCACCGGCTGATGCCAGTCGCCCTGCTGGCCCAGGCGATGGGCGACCAAA
 TCTGCGCATGAAGTTCCAGGGCGCCTTCCGCAAGGGGGTGCCCAACCCCATCGATCTG
 CTGGAGTCCACCTATATGAGTCCTCGGTGGTGCCTGGGCCCCAAGAAAGCACCCATGG
 15 ACTCACTGTTTGACTACGGCACCTATCGTCACCACTCCAGTGACAACAAGAGGTGGAG
 GAAGAAGATCATAGAGAAGCAGCCGCAGAGCCCCAAAGCCCCTGCCCTCAGCCGCC
 CCCCATCCTCAAAGTCTTCAACCGGCCTATCCTCTTTGACATCGTGTCCCGGGGCTCCA
 CTGCTGACCTGGACGGGCTGCTCCCATTTCTTGCTGACCCACAAGAAACGCCTAACTGA
 TGAGGAGTTTCGAGAGCCATCTACGGGGAAGACCTGCCTGCCCAAGGCCTTGCTGAAC
 20 CTGAGCAATGGCCGCAACGACACCATCCCTGTGCTGCTGGACATCGCGGAGCGCACCG
 GCAACATGCGGGAGTTCATTAACCTCGCCCTTCCGTGACATCTACTATCGAGGTCAGAC
 AGCCCTGCACATCGCCATTGAGCGTCGCTGAAACACTACGTGGAACCTTCTCGTGGCC
 CAGGGAGCTGATGTCCAAGCCAGGCCCGTGGGCGCTTCTTCCAGCCCAAGGATGAGG
 GGGGCTACTTCTACTTTGGGGAGCTGCCCTGTGCTGGCTGCCTGCACCAACCAGCCC
 25 CACATTGTCAACTACCTGACGGAGAACCCCCACAAGAAGGCGGACATGCGGCGCCAG
 GACTCGCGAGGCAACACAGTGCTGCATGCGCTGGTGGCCATTGCTGACAACACCCGTG
 AGAACACCAAGTTTGTACCAAGATGTACGACCTGCTGCTGCTCAAGTGTGCCCCGCT
 CTTCCCCGACAGCAACCTGGAGGCCGTGCTCAACAACGACGGCCTCTCGCCCCTCATG
 ATGGCTGCCAAGACGGGCAAGATTGGGATCTTTCAGCACATCATCCGGCGGGAGGTGA
 30 CGGATGAGGACACACGGCACCTGTCCCGCAAGTTCAAGGACTGGGCCTATGGGCCAGT
 GTATTCCTCGCTTTATGACCTCTCCTCCCTGGACACGTGTGGGGAAGAGGCCTCCGTGC
 TGGAGATCCTGGTGTACAACAGCAAGATTGAGAACCGCCACGAGATGCTGGCTGTGGA
 GCCCATCAATGAACTGCTGCGGGACAAGTGGCGCAAGTTCGGGGCCGTCTCCTTCTAC
 ATCAACGTGGTCTCCTACCTGTGTGCCATGGTCATCTTCACTCTCACCGCCTACTACCA
 35 GCCGCTGGAGGGCACACCGCCGTACCCTTACCGCACCACGGTGGACTACCTGCGGCTG

GCTGGCGAGGTCATTACGCTCTTCACTGGGGTCCTGTTCTTCTTCACCAACATCAAAGA
 CTTGTTCATGAAGAAATGCCCTGGAGTGAATTCTCTCTTCATTGATGGCTCCTTCCAGC
 TGCTCTACTTCATCTACTCTGTCCTGGTGATCGTCTCAGCAGCCCTCTACCTGGCAGGG
 ATCGAGGCCTACCTGGCCGTGATGGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCCCT
 5 TTA CTTCACCCGTGGGCTGAAGCTGACGGGGACCTATAGCATCATGATCCAGAAGATT
 CTCTTCAAGGACCTTTTCCGATTCTCTGCTCGTCTACTTGCTCTTCATGATCGGCTACGCT
 TCAGCCCTGGTCTCCCTCCTGAACCCGTGTGCCAACATGAAGGTGTGCAATGAGGACC
 AGACCAACTGCACAGTGCCCACTTACCCCTCGTGCCGTGACAGCGAGACCTTCAGCAC
 CTTCTCCTGGACCTGTTTAAGCTGACCATCGGCATGGGCGACCTGGAGATGCTGAGC
 10 AGCACCAAGTACCCCGTGGTCTTCATCATCTGCTGGTGACCTACATCATCCTCACCTT
 TGTGCTGCTCCTCAACATGCTCATTGCCCTCATGGGCGAGACAGTGGGCCAGGTCTCCA
 AGGAGAGCAAGCACATCTGGAAGCTGCAGTGGGCCACCACCATCCTGGACATTGAGC
 GCTCCTTCCCCGTATTCCTGAGGAAGGCCTTCCGCTCTGGGGAGATGGTCACCGTGGGC
 AAGAGCTCGGACGGCACTCCTGACCGCAGGTGGTGCTTCAGGGTGGATGAGGTGAACT
 15 GGTCTCACTGGAACCAGAACTTGGGCATCATCAACGAGGACCCGGGCAAGAATGAGA
 CCTACCAGTATTATGGCTTCTCGCATACCGTGGGCCGCCTCCGCAGGGATCGCTGGTCC
 TCGGTGGTACCCCGCGTGGTGGAAGTGAACAAGAACTCGAACCCGGACGAGGTGGTG
 GTGCCTCTGGACAGCATGGGGAACCCCGCTGCGATGGCCACCAGCAGGGTTACCCCG
 GCAAGTGGAGGACTGAGGACGCCCCGCTCTAGGGACTGCAGCCCAGCCCCAGCTTCTC
 20 TGCCCACTCATTTCTAGTCCAGCCGATTTTTCAGCAGTGCCTTCTGGGGTGTCCCCCAC
 ACCCTGCTTTGGCCCCAGAGGCGAGGGACCAGTGGAGGTGCCAGGGAGGCCCCAGGA
 CCCTGTGGTCCCCTGGCTCTGCCTCCCCACCCTGGGGTGGGGGCTCCCGGCCACCTGTC
 TTGCTCCTATGGAGTCACATAAGCCAACGCCAGAGCCCCTCCACCTCAGGCCCCAGCC
 CCTGCCTCTCCATTATTTATTTGCTCTGCTCTCAGGAAGCGACGTGACCCCTGCCCCAG
 25 CTGGAACCTGGCAGAGGCCTTAGGACCCCGTTCCAAGTGCAGTGGCCGGCCAAGCCCC
 AGCCTCAGCCTGCGCCTGAGCTGCATGCGCCACCATTTTTGGCAGCGTGGCAGCTTTGC
 AAGGGGCTGGGGCCCTCGGCGTGGGGCCATGCCTTCTGTGTGTTCTGTAGTGTCTGGG
 ATTTGCCGGTGTCTAATAAATGTTTATTCATTGACGGTGAAAAAAAAAAAAAAAAAAAA
 or a partial sequence thereof, a nucleic acid which is capable of hybridising with said
 30 sequence under stringent conditions, an allelic variant or a functional variant of said
 sequence or a variant of nucleic acid on the basis of the degenerative code.

14. Nucleic acid, characterised in that it has the sequence

CTCTCACCGCCTACTACCAGCCGCTGGAGGGCACAATGGCGGATTCCAGCGAAGGCCC
 35 CCGCGCGGGGCCCCGGGGAGGTGGCTGAGCTCCCCGGGGATGAGAGTGGCACCCCAGG

TGGGGAGGCTTTTCCTCTCTCCTCCCTGGCCAATCTGTTTGAGGGGGAGGATGGCTCCC
 TTTTCGCCCTCACCGGCTGATGCCAGTCGCCCTGCTGGCCCAGGCGATGGGCGACCAAA
 TCTGCGCATGAAGTTCCAGGGCGCCTTCCGCAAGGGGGTGCCCAACCCCATCGATCTG
 CTGGAGTCCACCCTATATGAGTCCTCGGTGGTGCCTGGGCCCCAAGAAAGCACCCATGG
 5 ACTCACTGTTTGACTACGGCACCTATCGTCACCACTCCAGTGACAACAAGAGGTGGAG
 GAAGAAGATCATAGAGAAGCAGCCGCAGAGCCCCAAAGCCCCTGCCCTCAGCCGCC
 CCCCATCCTCAAAGTCTTCAACCGGCCTATCCTCTTTGACATCGTGTCCCGGGGCTCCA
 CTGCTGACCTGGACGGGCTGCTCCCATTTCTTGCTGACCCACAAGAAACGCCTAACTGA
 TGAGGAGTTTCGAGAGCCATCTACGGGGAAGACCTGCCTGCCCAAGGCCTTGCTGAAC
 10 CTGAGCAATGGCCGCAACGACACCATCCCTGTGCTGCTGGACATCGCGGAGCGCACCG
 GCAACATGCGGGAGTTCATTAACCTCGCCCTTCCGTGACATCTACTATCGAGGTCAGAC
 AGCCCTGCACATCGCCATTGAGCGTCGCTGCAAACACTACGTGGAACCTTCGTGGCC
 CAGGGAGCTGATGTCCACGCCCAGGCCCGTGGGCGCTTCTTCCAGCCCAAGGATGAGG
 GGGGCTACTTCTACTTTGGGGAGCTGCCCTGTGCTGGCTGCCTGCACCAACCAGCCC
 15 CACATTGTCAACTACCTGACGGAGAACCCCCACAAGAAGGCGGACATGCGGCGCCAG
 GACTCGCGAGGCAACACAGTGCTGCATGCGCTGGTGGCCATTGCTGACAACACCCGTG
 AGAACACCAAGTTTGTACCAAGATGTACGACCTGCTGCTGCTCAAGTGTGCCCCGCT
 CTTCCCCGACAGCAACCTGGAGGGCCGTGCTCAACAACGACGGCCTCTCGCCCCTCATG
 ATGGCTGCCAAGACGGGCAAGATTGGGATCTTTCAGCACATCATCCGGCGGGAGGTGA
 20 CGGATGAGGACACACGGCACCTGTCCCGCAAGTTCAAGGACTGGGCCTATGGGCCAGT
 GTATTCCTCGCTTTATGACCTCTCCTCCCTGGACACGTGTGGGGAAGAGGCCTCCGTGC
 TGGAGATCCTGGTGTACAACAGCAAGATTGAGAACCGCCACGAGATGCTGGCTGTGGA
 GCCCATCAATGAACTGCTGCGGGACAAGTGGCGCAAGTTCGGGGCCGTCTCCTTCTAC
 ATCAACGTGGTCTCCTACCTGTGTGCCATGGTCATCTTCACTCTCACCGCCTACTACCA
 25 GCCGCTGGAGGGCACACCGCCGTACCCTTACCGCACCACGGTGGACTACCTGCGGCTG
 GCTGGCGAGGTCATTACGCTCTTCACTGGGGTCCTGTTCTTCTTACCAACATCAAAGA
 CTTGTTTCATGAAGAAATGCCCTGGAGTGAATTCTCTCTTCATTGATGGCTCCTTCCAGC
 TGCTCTACTTCATCTACTCTGTCTGCTGATCGTCTCAGCAGCCCTCTACCTGGCAGGG
 ATCGAGGCCTACCTGGCCGTGATGGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCCCT
 30 TTACTTACCCCGTGGGCTGAAGCTGACGGGGACCTATAGCATCATGATCCAGAAGATT
 CTCTTCAAGGACCTTTTCCGATTCCCTGCTCGTCTACTTGCTCTTCATGATCGGCTACGCT
 TCAGCCCTGGTCTCCCTCCTGAACCCGTGTGCCAACATGAAGGTGTGCAATGAGGACC
 AGACCAACTGCACAGTGCCCACTTACCCCTCGTGCCGTGACAGCGAGACCTTCAGCAC
 CTTCTCCTGGACCTGTTTAAGCTGACCATCGGCATGGGCGACCTGGAGATGCTGAGC
 35 AGCACCAAGTACCCCGTGGTCTTCATCATCCTGCTGGTGACCTACATCATCCTCACCTT
 TGTGCTGCTCCTCAACATGCTCATTGCCCTCATGGGCGAGACAGTGGGCCAGGTCTCCA

AGGAGAGCAAGCACATCTGGAAGCTGCAGTGGGCCACCACCATCCTGGACATTGAGC
 GCTCCTTCCCCGTATTCTGAGGAAGGCCTTCCGCTCTGGGGAGATGGTCACCGTGGGC
 AAGAGCTCGGACGGCACTCCTGACCGCAGGTGGTGGCTTCAGGGTGGATGAGGTGAACT
 GGTCTCACTGGAACCAGAACTTGGGCATCATCAACGAGGACCCGGGCAAGAATGAGA
 5 CCTACCAGTATTATGGCTTCTCGCATACCGTGGGCCGCCTCCGCAGGGATCGCTGGTCC
 TCGGTGGTACCCCGCGTGGTGGAACTGAACAAGAACTCGAACCCGGACGAGGTGGTG
 GTGCCTCTGGACAGCATGGGGAACCCCGCTGCGATGGCCACCAGCAGGGTTACCCCG
 GCAAGTGGAGGACTGAGGACGCCCCGCTCTAGGGACTGCAGCCCAGCCCCAGCTTCTC
 TGCCCACTCATTCTAGTCCAGCCGCATTTAGCAGTGCCTTCTGGGGTGTCCCCCAC
 10 ACCCTGCTTTGGCCCCAGAGGCGAGGGACCAAGTGGAGGTGCCAGGGAGGCCCCAGGA
 CCCTGTGGTCCCCTGGCTCTGCCTCCCCACCCTGGGGTGGGGGCTCCCGGCCACCTGTC
 TTGCTCCTATGGAGTCACATAAGCCAACGCCAGAGCCCCCTCCACCTCAGGCCCCAGCC
 CCTGCCTCTCCATTATTTATTTGCTCTGCTCTCAGGAAGCGACGTGACCCCTGCCCCAG
 CTGGAACCTGGCAGAGGCCCTTAGGACCCCGTTCCAAGTGCAGTGGCCGGCCAAGCCCC
 15 AGCCTCAGCCTGCGCCTGAGCTGCATGCGCCACCATTTTTGGCAGCGTGGCAGCTTTGC
 AAGGGGCTGGGGCCCTCGGCGTGGGGCCATGCCTTCTGTGTGTTCTGTAGTGTCTGGG
 ATTTGCCGGTGCTCAATAAATGTTTATTCATTGACGGTGAAAAAAAAAAAAAAAAAAAAA
 .

20 15. Nucleic acid, characterised in that it contains the sequence
 ATGGCGGATTCCAGCGAAGGCCCCCGCGCGGGGCCCGGGGAGGTGGCTGAGCTCCCC
 GGGGATGAGAGTGGCACCCCAGGTGGGGAGGCTTTTCTCTCTCCTCCCTGGCCAATC
 TGTTTGAGGGGGAGGATGGCTCCCTTTCGCCCTCACCGGCTGATGCCAGTCGCCCTGCT
 GGCCAGGCGATGGGCGACCAAATCTGCGCATGAAGTTCCAGGGCGCCTTCCGCAAGG
 25 GGGTGCCCAACCCCATCGATCTGCTGGAGTCCACCCTATATGAGTCCTCGGTGGTGCCT
 GGGCCCAAGAAAGCACCCATGGACTCACTGTTTGACTACGGCACCTATCGTCACCACT
 CCAGTGACAACAAGAGGTGGAGGAAGAAGATCATAGAGAAGCAGCCGCAGAGCCCCA
 AAGCCCCCTGCCCCCTCAGCCGCCCCCATCCTCAAAGTCTTCAACCGGCCTATCCTCTTT
 GACATCGTGTCCCGGGGCTCCACTGCTGACCTGGACGGGCTGCTCCCATCTTGCTGAC
 30 CCACAAGAAACGCCTAACTGATGAGGAGTTTCGAGAGCCATCTACGGGGAAGACCTG
 CCTGCCCAAGGCCTTGCTGAACCTGAGCAATGGCCGCAACGACACCATCCCTGTGCTG
 CTGGACATCGCGGAGCGCACCGGCAACATGCGGGAGTTCATTAACCTCGCCCTTCCGTG
 ACATCTACTATCGAGGTCAGACAGCCCTGCACATCGCCATTGAGCGTCGCTGCAAACA
 CTACGTGGAACCTTCTCGTGGCCCAGGGAGCTGATGTCCAAGCCCAGGCCCGTGGGCGC
 35 TTCTTCCAGCCCAAGGATGAGGGGGGCTACTTCTACTTTGGGGAGCTGCCCCGTGCGCT
 GGCTGCCTGCACCAACCAGCCCCACATTGTCAACTACCTGACGGAGAACCCCCACAAG

AAGGCGGACATGCGGCGCCAGGACTCGCGAGGCAACACAGTGCTGCATGCGCTGGTG
 GCCATTGCTGACAACACCCGTGAGAACACCAAGTTTGTACCAAGATGTACGACCTGC
 TGCTGCTCAAGTGTGCCCCGCTCTTCCCCGACAGCAACCTGGAGGCCGTGCTCAACAA
 CGACGGCCTCTCGCCCCCTCATGATGGCTGCCAAGACGGGCAAGATTGGGATCTTTCAG
 5 CACATCATCCGGCGGGAGGTGACGGATGAGGACACACGGCACCTGTCCCGCAAGTTCA
 AGGACTGGGCCTATGGGCCAGTGTATTCTCGCTTTATGACCTCTCCTCCCTGGACACG
 TGTGGGGAAGAGGCCTCCGTGCTGGAGATCCTGGTGTACAACAGCAAGATTGAGAACC
 GCCACGAGATGCTGGCTGTGGAGCCCATCAATGAACTGCTGCGGGACAAGTGGCGCA
 AGTTCGGGGCCGTCTCCTTCTACATCAACGTGGTCTCCTACCTGTGTGCCATGGTCATC
 10 TTCACTCTACCCGCCTACTACCAGCCGCTGGAGGGCACACCGCCGTACCCTTACCGCAC
 CACGGTGGACTACCTGCGGCTGGCTGGCGAGGTCATTACGCTCTTCACTGGGGTCTGT
 TCTTCTTACCAACATCAAAGACTTGTTTCATGAAGAAATGCCCTGGAGTGAATTCTCTC
 TTCATTGATGGCTCCTTCCAGCTGCTCTACTTCATCTACTCTGTCTGCTGGTGATCGTCTCA
 GCAGCCCTCTACCTGGCAGGGATCGAGGCCTACCTGGCCGTGATGGTCTTTGCCCTGGT
 15 CCTGGGCTGGATGAATGCCCTTTACTTCACCCGTGGGCTGAAGCTGACGGGGACCTAT
 AGCATCATGATCCAGAAGATTCTCTTCAAGGACCTTTTCCGATTCTGCTCGTCTACTT
 GCTCTTCATGATCGGCTACGCTTCAGCCCTGGTCTCCCTCCTGAACCCGTGTGCCAACA
 TGAAGGTGTGCAATGAGGACCAGACCAACTGCACAGTGCCCACTTACCCCTCGTGCCG
 TGACAGCGAGACCTTCAGCACCTTCCTCCTGGACCTGTTTAAGCTGACCATCGGCATGG
 20 GCGACCTGGAGATGCTGAGCAGCACCAAGTACCCCGTGGTCTTCATCATCCTGCTGGT
 GACCTACATCATCCTCACCTTTGTGCTGCTCCTCAACATGCTCATTGCCCTCATGGGCG
 AGACAGTGGGCCAGGTCTCCAAGGAGAGCAAGCACATCTGGAAGCTGCAGTGGGCCA
 CCACCATCCTGGACATTGAGCGCTCCTTCCCCGTATTCTGAGGAAGGCCTTCCGCTCT
 GGGGAGATGGTCACCGTGGGCAAGAGCTCGGACGGCACTCCTGACCGCAGGTGGTGC
 25 TTCAGGGTGGATGAGGTGAACTGGTCTCACTGGAACCAGAACTTGGGCATCATCAACG
 AGGACCCGGGCAAGAATGAGACCTACCAGTATTATGGCTTCTCGCATAACCGTGGGCCG
 CCTCCGCAGGGATCGCTGGTCTCGGTGGTACCCCGCTGGTGGAACTGAACAAGAAC
 TCGAACCCGGACGAGGTGGTGGTGCCTCTGGACAGCATGGGGAACCCCGCTGCGATG
 GCCACCAGCAGGGTTACCCCGCAAGTGGAGGACTGAGGACGCCCCGCTCTAG
 30 or a partial sequence thereof, a nucleic acid which is capable of hybridising with said
 sequence under stringent conditions, an allelic variant or a functional variant of said
 sequence or a variant of nucleic acid on the basis of the degenerative code.

16. Nucleic acid, characterised in that it has the sequence

ATGGCGGATTCCAGCGAAGGCCCCGCGCGGGGCCCCGGGGAGGTGGCTGAGCTCCCC
 GGGGATGAGAGTGGCACCCCAGGTGGGGAGGCTTTTCCTCTCTCCTCCCTGGCCAATC
 TGTTTGAGGGGGAGGATGGCTCCCTTTCGCCCTCACCGGCTGATGCCAGTCGCCCTGCT
 GGGCCAGGCGATGGGCGACCAAATCTGCGCATGAAGTTCCAGGGCGCCTTCCGCAAGG
 5 GGGTGCCCAACCCCATCGATCTGCTGGAGTCCACCCTATATGAGTCCTCGGTGGTGCCT
 GGGCCCAAGAAAGCACCCATGGACTCACTGTTTGACTACGGCACCTATCGTCACCACT
 CCAGTGACAACAAGAGGTGGAGGAAGAAGATCATAGAGAAGCAGCCGCAGAGCCCCA
 AAGCCCCTGCCCTCAGCCGCCCCCATCCTCAAAGTCTTCAACCGGCCTATCCTCTTT
 GACATCGTGTCCCGGGGCTCCACTGCTGACCTGGACGGGCTGCTCCCATCTTGCTGAC
 10 CCACAAGAAACGCCTAACTGATGAGGAGTTTCGAGAGCCATCTACGGGGAAGACCTG
 CCTGCCCAAGGCCTTGCTGAACCTGAGCAATGGCCGCAACGACACCATCCCTGTGCTG
 CTGGACATCGCGGAGCGCACCGGCAACATGCGGGAGTTCAATTAACCTCGCCCTTCCGTG
 ACATCTACTATCGAGGTCAGACAGCCCTGCACATCGCCATTGAGCGTCGCTGCAAACA
 CTACGTGGAACCTTCTCGTGGCCCAGGGAGCTGATGTCCAAGCCCAGGCCCGTGGGCGC
 15 TTCTTCCAGCCCAAGGATGAGGGGGGCTACTTCTACTTTGGGGAGCTGCCCCCTGTCGCT
 GGCTGCCTGCACCAACCAGCCCCACATTGTCAACTACCTGACGGAGAACCCCCACAAG
 AAGGCGGACATGCGGCGCCAGGACTCGCGAGGCAACACAGTGCTGCATGCGCTGGTG
 GCCATTGCTGACAACACCCGTGAGAACACCAAGTTTGTTACCAAGATGTACGACCTGC
 TGCTGCTCAAGTGTGCCCCGCTCTTCCCCGACAGCAACCTGGAGGCCGTGCTCAACAA
 20 CGACGGCCTCTCGCCCCTCATGATGGCTGCCAAGACGGGCAAGATTGGGATCTTTTACG
 CACATCATCCGGCGGGAGGTGACGGATGAGGACACACGGCACCTGTCCCGCAAGTTCA
 AGGACTGGGCCTATGGGCCAGTGTATTCTCGCTTTATGACCTCTCCTCCCTGGACACG
 TGTGGGGAAGAGGCCTCCGTGCTGGAGATCCTGGTGTACAACAGCAAGATTGAGAACC
 GCCACGAGATGCTGGCTGTGGAGCCCATCAATGAACTGCTGCGGGACAAGTGGCGCA
 25 AGTTCGGGGCCGTCTCCTTCTACATCAACGTGGTCTCCTACCTGTGTGCCATGGTCATC
 TTCCTCTCACCGCCTACTACCAGCCGTGGAGGGCACACCGCCGTACCCTTACCGCAC
 CACGGTGGACTACCTGCGGCTGGCTGGCGAGGTCATTACGCTCTTCACTGGGGTCCTGT
 TCTTCTTACCAACATCAAAGACTTGTTTCATGAAGAAATGCCCTGGAGTGAATTCTCTC
 TTCATTGATGGCTCCTTCCAGCTGCTCTACTTCATCTACTCTGTCTGCTGGTGATCGTCTCA
 30 GCAGCCCTCTACCTGGCAGGGATCGAGGCCTACCTGGCCGTGATGGTCTTTGCCCTGGT
 CCTGGGCTGGATGAATGCCCTTTACTTCACCCGTGGGCTGAAGCTGACGGGGACCTAT
 AGCATCATGATCCAGAAGATTCTCTTCAAGGACCTTTTCCGATTCTGCTCGTCTACTT
 GCTCTTCATGATCGGCTACGCTTCAGCCCTGGTCTCCCTCCTGAACCCGTGTGCCAACA
 TGAAGGTGTGCAATGAGGACCAGACCAACTGCACAGTGCCCACTTACCCCTCGTGCCG
 35 TGACAGCGAGACCTTCAGCACCTTCCTCCTGGACCTGTTTAAGCTGACCATCGGCATGG
 GCGACCTGGAGATGCTGAGCAGCACCAAGTACCCCGTGGTCTTCATCATCCTGCTGGT

GACCTACATCATCCTCACCTTTGTGCTGCTCCTCAACATGCTCATTGCCCTCATGGGCG
 AGACAGTGGGCCAGGTCTCCAAGGAGAGCAAGCACATCTGGAAGCTGCAGTGGGCCA
 CCACCATCCTGGACATTGAGCGCTCCTTCCCCGTATTCCTGAGGAAGGCCTTCCGCTCT
 GGGGAGATGGTCACCGTGGGCAAGAGCTCGGACGGCACTCCTGACCGCAGGTGGTGC
 5 TTCAGGGTGGATGAGGTGAACTGGTCTCACTGGAACCAGAACTTGGGCATCATCAACG
 AGGACCCGGGCAAGAATGAGACCTACCAGTATTATGGCTTCTCGCATACCGTGGGCCG
 CCTCCGCAGGGATCGCTGGTCCTCGGTGGTACCCCGCGTGGTGGAACTGAACAAGAAC
 TCGAACCCGGACGAGGTGGTGGTGCCTCTGGACAGCATGGGGAACCCCCGCTGCGATG
 GCCACCAGCAGGGTTACCCCCGCAAGTGGAGGACTGAGGACGCCCCGCTCTAG.

10

17. Nucleic acid, characterised in that it comprises the sequence

GGCCACGCGTCGACTAGTACGGGGGGGGGGGGGGGGGGTGGCRGSRGGAKCAGGACTC
 GGCCGGAGGGATCAGGAAGCGGCGGCGCTGCGCCCGCGTCCTGAGGCTGAGAAGTAC
 AAACAGATCTGGGTCCAGTATGGCAGATCCTGGTGATGGTCCCCGTGCAGCGCCTGGG
 15 GAGGTGGCTGAGCCCCCTGGAGATGAGAGTGGTACCTCTGGTGGGGAGGCCTTCCCCC
 TCTCTTCCCTGGCCAATCTGTTTGAGGGGGAGGAAGGCTCCTCTTCTTTCCCCGGTG
 GATGCTAGCCGCCCTGCTGGCCCTGGCGATGGACGTCCAAACCTGCGTATGAAGTTCC
 AGGGCGCTTTCCGCAAGGGGGTTCCCAACCCCATTGACCTGTTGGAGTCCACCCGGTA
 CGAGTCCTCAGTAGTGCCTGGGCCCAAGAAAGCGCCCATGGATTCTTGTTCGACTAC
 20 GGCACCTACCGTCACCACCCCAGTGACAACAAGAGATGGAGGAGAAAGGTCGTGGAG
 AAGCAGCCACAGAGCCCCAAAGCTCCTGCACCCCAGCCACCCCCCATCCTCAAAGTCT
 TCAATCGGCCCATCCTCTTTGACATTGTGTCCCGGGGCTCCACTGCGGACCTAGATGGA
 CTGCTCTCCTTCTTGTGACCCACAAGAAGCGCCTGACTGATGAGGAGTTCGGGGAGC
 CGTCCACGGGGAAGACCTGCCTGCCCAAGGCGCTGCTGAACCTAAGCAACGGGCGCA
 25 ACGACACCATCCCGGTGTTGCTGGACATTGCGGAGCGCACCGGCAACATGCGTGAATT
 CATCAACTCGCCCTTCAGAGACATCTACTACCGAGGCCAGACATCCCTGCACATTGCC
 ATCGAACGGCGCTGCAAGCACTACGTGGAGCTGCTGGTGGCCCAGGGAGCCGACGTG
 CACGCCCAGGCCCGCGGCCGCTTCTTCCAGCCCAAGGATGAGGGAGGCTACTTCTACT
 TTGGGGAGCTGCCCTTGTCCCTGGCAGCCTGCACCAACCAGCCGCACATCGTCAACTA
 30 CCTGACAGAGAACCCTCACAAGAAAGCTGACATGAGGCGACAGGACTCGAGGGGGAA
 CACGGTGCTGCACGCGCTGGTGGCCATCGCCGACAACACCCGAGAGAACACCAAGTTT
 GTCACCAAGATGTACGACCTGCTGCTTCTCAAGTGTTACGCTCTTCCCCGACAGCAA
 CCTGGAGACAGTTCTCAACAATGATGGCCTTTCGCCTCTCATGATGGCTGCCAAGACA
 GGCAAGATCGGGGTCTTTCAGCACATCATCCGACGTGAGGTGACAGATGAGGACACCC
 35 GGCATCTGTCTCGCAAGTTCAAGGACTGGGCCTATGGGCCTGTGTATTCTTCTCTTAC
 GACCTCTCCTCCCTGGACACATGCGGGGAGGAGGTGTCCGTGCTGGAGATCCTGGTGT

ACAACAGCAAGATCGAGAACCGCCATGAGATGCTGGCTGTAGAGCCCATTAACGAAC
 TGTTGAGAGACAAGTGGCGTAAGTTTGGGGCTGTGTCCTTCTACATCAACGTGGTCTCC
 TATCTGTGTGCCATGGTCATCTTCACCCTCACCGCCTACTATCAGCCACTGGAGGGCAC
 GCCACCCTACCCTTACCGGACCACAGTGGACTACCTGAGGCTGGCTGGCGAGGTCATC
 5 ACGCTCTTCACAGGAGTCCTGTTCTTCTTTACCAGTATCAAAGACTTGTTACGAAGAA
 ATGCCCTGGAGTGAATTCTCTCTTCGTCGATGGCTCCTTCCAGTTACTCTACTTCATCTA
 CTCTGTGCTGGTGGTTGTCTCTGCGGCGCTCTACCTGGCTGGGATCGAGGCCTACCTGG
 CTGTGATGGTCTTTGGCCCTGGTCCTGGGCTGGATGAATGCGCTGTACTTCACGCGCGGG
 TTGAAGCTGACGGGGACCTACAGCATCATGATTCAGAAGATCCTCTTCAAAGACCTCT
 10 TCCGCTTCCTGCTTGTGTACCTGCTCTTCATGATCGGCTATGCCTCAGCCCTGGTCACCC
 TCCTGAATCCGTGCACCAACATGAAGGTCTGTGACGAGGACCAGAGCAACTGCACGGT
 GCCACGTATCCTGCGTGCCGCGACAGCGAGACCTTCAGCGCCTTCCTCCTGGACCTCT
 TCAAGCTCACCATCGGCATGGGAGACCTGGAGATGCTGAGCAGCGCCAAGTACCCCGT
 GGTCTTCATCCTCCTGCTGGTCACCTACATCATCCTCACCTTCGTGCTCCTGTTGAACAT
 15 GCTTATCGCCCTCATGGGTGAGACCGTGGGCCAGGTGTCCAAGGAGAGCAAGCACATC
 TGGAAGTTGCAGTGGGCCACCACCATCCTGGACATCGAGCGTTCCTTCCCTGTGTTCTC
 GAGGAAGGCCTTCCGCTCCGGAGAGATGGTGACTGTGGGCAAGAGCTCAGATGGCAC
 TCCGGACCGCAGGTGGTGCTTCAGGGTGGACGAGGTGAACTGGTCTCACTGGAACCAG
 AACTTGGGCATCATTAACGAGGACCCTGGCAAGAGTGAAATCTACCAGTACTATGGCT
 20 TCTCCCACACCGTGGGGCGCCTTCGTAGGGATCGTTGGTCTCGGTGGTGGCCCGCGTA
 GTGGAGCTGAACAAGAACTCAAGCGCAGATGAAGTGGTGGTACCCCTGGATAACCTA
 GGAACCCCAACTGTGACGGCCACCAGCAGGGCTACGCTCCCAAGTGGAGGACGGAC
 GATGCCCCACTGTAGGGGCCGTGCCAGAGCTCGCACAGATAGTCCAGGCTTGGCCTTC
 GCTCCCACCTACATTTAGGCATTTGTCCGGTGTCTTCCCACACCCGCATGGGACCTTGG
 25 AGGTGAGGGCCTCTGTGGCGACTCTGTGGAGGCCCCAGGACCCTCTGGTCCCCGCCAA
 GACTTTTGCCTTCAGCTCTACTCCCCACATGGGGGGGCGGGGCTCCTGGCTACCTGTCT
 CGCTCGCTCCCATGGAGTCACCTAAGCCAGCACAAGGCCCTCTCCTCGAAAGGCTCA
 GGCCCCATCCCTCTTGTGTATTATTATTGCTCTCCTCAGGAAAATGGGGTGGCAGGAG
 TCCACCCGCGGCTGGAACCTGGCCAGGGCTGAAGCTCATGCAGGGACGCTGCAGCTCC
 30 GACCTGCCACAGATCTGACCTGCTGCAGCCCTGGCTAGTGTGGGTCTTCTGTACTTTGA
 AGAGATCGGGGCCGCTGGTGCTCAATAAATGTTTATTCTCGGTGGAAAAAAAAAAAAAA
 AAA
 AAAAAAAAA

or a partial sequence thereof, a nucleic acid which is capable of hybridising with said
 35 sequence under stringent conditions, an allelic variant or a functional variant of said

sequence or a variant of the nucleic acid on the basis of the degenerative code, wherein R may be an A or G, M may be an A or C, S may be a C or G, Y may be a C or T, K may be a G or T and W may be an A or T.

5 18. Nucleic acid, characterised in that it has the sequence

GGCCACGCGTCGACTAGTACGGGGGGGGGGGGGGGGGGTGGCRGSRGGAKCAGGACTC
GGCCGGAGGGATCAGGAAGCGGCGGCGCTGCGCCCGCGTCCTGAGGCTGAGAAGTAC
AAACAGATCTGGGTCCAGTATGGCAGATCCTGGTGTATGGTCCCCGTGCAGCGCCTGGG
GAGGTGGCTGAGCCCCCTGGAGATGAGAGTGGTACCTCTGGTGGGGAGGCCTTCCCCC
10 TCTCTTCCCTGGCCAATCTGTTTGAAGGGGAGGAAGGCTCCTCTTCTCTTTCCCCGGTG
GATGCTAGCCGCCCTGCTGGCCCTGGCGATGGACGTCCAAACCTGCGTATGAAGTTCC
AGGGCGCTTTCCGCAAGGGGGTTCCCAACCCCATTGACCTGTTGGAGTCCACCCGGTA
CGAGTCCTCAGTAGTGCCTGGGCCCAAGAAAGCGCCCATGGATTCTTGTTCGACTAC
GGCACTTACCGTCACCACCCCAGTGACAACAAGAGATGGAGGAGAAAGGTCGTGGAG
15 AAGCAGCCACAGAGCCCCAAAGCTCCTGCACCCCAGCCACCCCCCATCCTCAAAGTCT
TCAATCGGCCCATCCTCTTTGACATTGTGTCCCGGGGCTCCACTGCGGACCTAGATGGA
CTGCTCTCCTTCTTGTGACCCACAAGAAGCGCCTGACTGATGAGGAGTTCCGGGAGC
CGTCCACGGGGAAGACCTGCCTGCCCAAGGCGCTGCTGAACCTAAGCAACGGGCGCA
ACGACACCATCCCGGTGTTGCTGGACATTGCGGAGCGCACCGGCAACATGCGTGAATT
20 CATCAACTCGCCCTTCAGAGACATCTACTACCGAGGCCAGACATCCCTGCACATTGCC
ATCGAACGGCGCTGCAAGCACTACGTGGAGCTGCTGGTGGCCCAGGGAGCCGACGTG
CACGCCAGGCCCCGCGGCCGCTTCTTCCAGCCCAAGGATGAGGGAGGCTACTTCTACT
TTGGGGAGCTGCCCTTGTCCCTGGCAGCCTGCACCAACCAGCCGCACATCGTCAACTA
CCTGACAGAGAACCCTCACAAGAAAGCTGACATGAGGCGACAGGACTCGAGGGGGAA
25 CACGGTGCTGCACGCGCTGGTGGCCATCGCCGACAACACCCGAGAGAAACCAAGTTT
GTCACCAAGATGTACGACCTGCTGCTTCTCAAGTGTTACGCCTCTTCCCCGACAGCAA
CCTGGAGACAGTTCTCAACAATGATGGCCTTTCGCCTCTCATGATGGCTGCCAAGACA
GGCAAGATCGGGGTCTTTCAGCACATCATCCGACGTGAGGTGACAGATGAGGACACCC
GGCATCTGTCTCGCAAGTTCAAGGACTGGGCCTATGGGCCTGTGTATTCTTCTCTCTAC
30 GACCTCTCCTCCCTGGACACATGCGGGGAGGAGGTGTCCGTGCTGGAGATCCTGGTGT
ACAACAGCAAGATCGAGAACCGCCATGAGATGCTGGCTGTAGAGCCCATTAACGAAC
TGTTGAGAGACAAGTGGCGTAAGTTTGGGGCTGTGTCCTTCTACATCAACGTGGTCTCC
TATCTGTGTGCCATGGTCATCTTACCCTCACCGCCTACTATCAGCCACTGGAGGGCAC
GCCACCCTACCCTTACCGGACCACAGTGGACTACCTGAGGCTGGCTGGCGAGGTCATC
35 ACGCTCTTACAGGAGTCCTGTTCTTCTTACCAGTATCAAAGACTTGTTACGAAGAA

ATGCCCTGGAGTGAATTCTCTCTTCGTCGATGGCTCCTTCCAGTTACTCTACTTCATCTA
 CTCTGTGCTGGTGGTTGTCTCTGCGGCGCTCTACCTGGCTGGGATCGAGGCCTACCTGG
 CTGTGATGGTCTTTGCCCTGGTCCTGGGCTGGATGAATGCGCTGTACTTCACGCGCGGG
 TTGAAGCTGACGGGGACCTACAGCATCATGATTCAGAAGATCCTCTTCAAAGACCTCT
 5 TCCGCTTCCTGCTTGTGTACCTGCTCTTCATGATCGGCTATGCCTCAGCCCTGGTCACCC
 TCCTGAATCCGTGCACCAACATGAAGGTCTGTGACGAGGACCAGAGCAACTGCACGGT
 GCCACGTATCCTGCGTGCCGCGACAGCGAGACCTTCAGCGCCTTCCTCCTGGACCTCT
 TCAAGCTCACCATCGGCATGGGAGACCTGGAGATGCTGAGCAGCGCCAAGTACCCCGT
 GGTCTTCATCCTCCTGCTGGTCACCTACATCATCCTCACCTTCGTGCTCCTGTTGAACAT
 10 GCTTATCGCCCTCATGGGTGAGACCGTGGGCCAGGTGTCCAAGGAGAGCAAGCACATC
 TGGAAGTTGCAGTGGGCCACCACCATCCTGGACATCGAGCGTTCCTTCCCTGTGTTCCCT
 GAGGAAGGCCTTCCGCTCCGGAGAGATGGTGACTGTGGGCAAGAGCTCAGATGGCAC
 TCCGGACCGCAGGTGGTGCTTCAGGGTGGACGAGGTGAACTGGTCTCACTGGAACCAG
 AACTTGGGCATCATTAACGAGGACCCTGGCAAGAGTGAAATCTACCAGTACTATGGCT
 15 TCTCCACACCGTGGGGCGCCTTCGTAGGGATCGTTGGTCCCTCGGTGGTGGCCCGCGTA
 GTGGAGCTGAACAAGAACTCAAGCGCAGATGAAGTGGTGGTACCCCTGGATAACCTA
 GGAACCCCAACTGTGACGGCCACCAGCAGGGCTACGCTCCCAAGTGGAGGACGGAC
 GATGCCCCACTGTAGGGGGCCGTGCCAGAGCTCGCACAGATAGTCCAGGCTTGGCCTTC
 GCTCCACCTACATTTAGGCATTTGTCCGGTGTCTTCCACACCCGCATGGGACCTTGG
 20 AGGTGAGGGCCTCTGTGGCGACTCTGTGGAGGGCCCCAGGACCCTCTGGTCCCCGCCAA
 GACTTTTGCCTTCAGCTCTACTCCCCACATGGGGGGGCGGGGCTCCTGGCTACCTGTCT
 CGCTCGCTCCCATGGAGTCACCTAAGCCAGCACAAGGCCCTCTCCTCGAAAGGCTCA
 GGCCCCATCCCTCTTGTGTATTATTTATTGCTCTCCTCAGGAAAATGGGGTGGCAGGAG
 TCCACCCGCGGCTGGAACCTGGCCAGGGCTGAAGCTCATGCAGGGACGCTGCAGCTCC
 25 GACCTGCCACAGATCTGACCTGCTGCAGCCCTGGCTAGTGTGGGTCTTCTGTACTTTGA
 AGAGATCGGGGCCGCTGGTGCTCAATAAATGTTTATTCTCGGTGGAAAAAAAAAAAAAA
 AAA
 AAAAAAAA,

wherein R may be an A or G, M may be an A or C, S may be a C or G, Y may be a C or T,
 30 K may be a G or T and W may be an A or T.

19. Nucleic acid, characterised in that it contains the sequence
 ATGGCAGATCCTGGTGATGGTCCCCGTGCAGCGCCTGGGGAGGTGGCTGAGCCCCCTG
 GAGATGAGAGTGGTACCTCTGGTGGGGAGGCCTTCCCCCTCTCTTCCCTGGCCAATCTG
 35 TTTGAGGGGGAGGAAGGCTCCTCTTCTTTTCCCCGGTGGATGCTAGCCGCCCTGCTGG

CCCTGGCGATGGACGTCCAAACCTGCGTATGAAGTTCCAGGGCGCTTTCCGCAAGGGG
 GTTCCCAACCCCAATTGACCTGTTGGAGTCCACCCGGTACGAGTCCTCAGTAGTGCCTGG
 GCCAAGAAAGCGCCCATGGATTCTTGTTCGACTACGGCACTTACCGTCACCACCCC
 AGTGACAACAAGAGATGGAGGAGAAAGGTCGTGGAGAAGCAGCCACAGAGCCCCAA
 5 AGCTCCTGCACCCCAGCCACCCCCCATCCTCAAAGTCTTCAATCGGCCCATCCTCTTTG
 ACATTGTGTCCCGGGGCTCCACTGCGGACCTAGATGGACTGCTCTCCTTCTTGTGACC
 CACAAGAAGCGCCTGACTGATGAGGAGTTCCGGGAGCCGTCCACGGGGAAGACCTGC
 CTGCCCAAGGCGCTGCTGAACCTAAGCAACGGGCGCAACGACACCATCCCGGTGTTGC
 TGGACATTGCGGAGCGCACCGGCAACATGCGTGAATTCATCAACTCGCCCTTCAGAGA
 10 CATCTACTACCGAGGCCAGACATCCCTGCACATTGCCATCGAACGGCGCTGCAAGCAC
 TACGTGGAGCTGCTGGTGGCCAGGGAGCCGACGTGCACGCCCAGGCCCGCGGCCGCT
 TCTTCCAGCCCAAGGATGAGGGAGGCTACTTCTACTTTGGGGAGCTGCCCTTGTCCCTG
 GCAGCCTGCACCAACCAGCCGCACATCGTCAACTACCTGACAGAGAACCCTCACAGA
 AAGCTGACATGAGGCGACAGGACTCGAGGGGGAACACGGTGCTGCACGCGCTGGTGG
 15 CCATCGCCGACAACACCCGAGAGAACACCAAGTTTGTACCAAGATGTACGACCTGCT
 GCTTCTCAAGTGTTACGCTCTTCCCCGACAGCAACCTGGAGACAGTTCTCAACAATG
 ATGGCCTTTCGCCTCTCATGATGGCTGCCAAGACAGGCAAGATCGGGGTCTTTCAGCA
 CATCATCCGACGTGAGGTGACAGATGAGGACACCCGGCATCTGTCTCGCAAGTTCAAG
 GACTGGGCCTATGGGCCTGTGTATTCTTCTCTCTACGACCTCTCCTCCCTGGACACATG
 20 CGGGGAGGAGGTGTCCGTGCTGGAGATCCTGGTGTACAACAGCAAGATCGAGAACCG
 CCATGAGATGCTGGCTGTAGAGCCCATTAACGAACTGTTGAGAGACAAGTGGCGTAAG
 TTTGGGGCTGTGTCTTCTACATCAACGTGGTCTCCTATCTGTGTGCCATGGTCATCTTC
 ACCCTCACCGCCTACTATCAGCCACTGGAGGGCACGCCACCCTACCCTTACCGGACCA
 CAGTGGACTACCTGAGGCTGGCTGGCGAGGTCATCACGCTCTTCACAGGAGTCCTGTT
 25 CTTCTTTACCAGTATCAAAGACTTGTTACGAAGAAATGCCCTGGAGTGAATTCTCTCT
 TCGTCGATGGCTCCTTCCAGTTACTCTACTTCATCTACTCTGTGCTGGTGGTTGTCTCTG
 CGGCGCTCTACCTGGCTGGGATCGAGGCCTACCTGGCTGTGATGGTCTTTGCCCTGGTC
 CTGGGCTGGATGAATGCGCTGTACTTCACGCGCGGGTTGAAGCTGACGGGGACCTACA
 GCATCATGATTCAGAAGATCCTCTTCAAAGACCTCTTCCGCTTCCTGCTTGTGTACCTG
 30 CTCTTCATGATCGGCTATGCCTCAGCCCTGGTCACCCTCCTGAATCCGTGCACCAACAT
 GAAGGTCTGTGACGAGGACCAGAGCAACTGCACGGTGCCACGTATCCTGCGTGCCGC
 GACAGCGAGACCTTCAGCGCCTTCCCTCCTGGACCTCTTCAAGCTCACCATCGGCATGG
 GAGACCTGGAGATGCTGAGCAGCGCCAAGTACCCCGTGGTCTTCATCCTCCTGCTGGT
 CACCTACATCATCCTCACCTTCGTGCTCCTGTTGAACATGCTTATCGCCCTCATGGGTG
 35 AGACCGTGGGCCAGGTGTCCAAGGAGAGCAAGCACATCTGGAAGTTGCAGTGGGCCA
 CCACCATCCTGGACATCGAGCGTTCCTTCCCTGTGTTCCCTGAGGAAGGCCTTCCGCTCC

GGAGAGATGGTGACTGTGGGCAAGAGCTCAGATGGCACTCCGGACCGCAGGTGGTGC
 TTCAGGGTGGACGAGGTGAACTGGTCTCACTGGAACCAGAACTTGGGCATCATTAAACG
 AGGACCCTGGCAAGAGTGAAATCTACCAGTACTATGGCTTCTCCCACACCGTGGGGCG
 CCTTCGTAGGGATCGTTGGTCCTCGGTGGTGCCCCGCGTAGTGGAGCTGAACAAGAAC
 5 TCAAGCGCAGATGAAGTGGTGGTACCCCTGGATAACCTAGGGAACCCCAACTGTGACG
 GCCACCAGCAGGGCTACGCTCCCAAGTGGAGGACGGACGATGCCCCACTGTAG

or a partial sequence thereof, a nucleic acid which is capable of hybridising with said
 sequence under stringent conditions, an allelic variant or a functional variant of said
 sequence or a variant of the nucleic acid on the basis of the degenerative code.

10

20. Nucleic acid, characterised in that it has the sequence

ATGGCAGATCCTGGTGATGGTCCCCGTGCAGCGCCTGGGGAGGTGGCTGAGCCCCCTG
 GAGATGAGAGTGGTACCTCTGGTGGGGAGGCCTTCCCCCTCTCTTCCCTGGCCAATCTG
 TTTGAGGGGGAGGAAGGCTCCTCTTCTCTTTCCCCGGTGGATGCTAGCCGCCCTGCTGG
 15 CCCTGGCGATGGACGTCCAAACCTGCGTATGAAGTTCCAGGGCGCTTCCGCAAGGGG
 GTTCCCAACCCCATTGACCTGTTGGAGTCCACCCGGTACGAGTCCTCAGTAGTGCCTGG
 GCCCAAGAAAGCGCCCATGGATTCTTGTTCGACTACGGCACTTACCGTCACCACCCC
 AGTGACAACAAGAGATGGAGGAGAAAGGTCGTGGAGAAGCAGCCACAGAGCCCCAA
 AGCTCCTGCACCCCAGCCACCCCCCATCCTCAAAGTCTTCAATCGGCCCATCCTCTTTG
 20 ACATTGTGTCCCGGGGCTCCACTGCGGACCTAGATGGACTGCTCTCCTTCTTGTGACC
 CACAAGAAGCGCCTGACTGATGAGGAGTTCCGGGAGCCGTCCACGGGGAAGACCTGC
 CTGCCCAAGGCGCTGCTGAACCTAAGCAACGGGCGCAACGACACCATCCCGGTGTTGC
 TGGACATTGCGGAGCGCACCGGCAACATGCGTGAATTCATCAACTCGCCCTTCAGAGA
 CATCTACTACCGAGGCCAGACATCCCTGCACATTGCCATCGAACGGCGCTGCAAGCAC
 25 TACGTGGAGCTGCTGGTGGCCCAGGGAGCCGACGTGCACGCCCAGGCCCGCGGGCCGCT
 TCTTCCAGCCCAAGGATGAGGGAGGCTACTTCTACTTTGGGGAGCTGCCCTTGTCCCTG
 GCAGCCTGCACCAACCAGCCGCACATCGTCAACTACCTGACAGAGAACCCTCACAGA
 AAGCTGACATGAGGCGACAGGACTCGAGGGGGAACACGGTGCTGCACGCGCTGGTGG
 CCATCGCCGACAACACCCGAGAGAACACCAAGTTTGTACCAAGATGTACGACCTGCT
 30 GCTTCTCAAGTGTTACGCCTCTTCCCCGACAGCAACCTGGAGACAGTTCTCAACAATG
 ATGGCCTTTCGCCTCTCATGATGGCTGCCAAGACAGGCAAGATCGGGGTCTTTCAGCA
 CATCATCCGACGTGAGGTGACAGATGAGGACACCCGGCATCTGTCTCGCAAGTTCAAG
 GACTGGGCCTATGGGCCTGTGTATTCTTCTCTACGACCTCTCCTCCCTGGACACATG
 CGGGGAGGAGGTGTCCGTGCTGGAGATCCTGGTGTACAACAGCAAGATCGAGAACCG
 35 CCATGAGATGCTGGCTGTAGAGCCCATTAACGAACCTGTTGAGAGACAAGTGGCGTAAG

TTTGGGGCTGTGTCCTTCTACATCAACGTGGTCTCCTATCTGTGTGCCATGGTCATCTTC
 ACCCTCACCGCCTACTATCAGCCACTGGAGGGCACGCCACCCTACCCTTACCGGACCA
 CAGTGGACTACCTGAGGCTGGCTGGCGAGGTCATCACGCTCTTCACAGGAGTCCTGTT
 CTTCTTTACCAGTATCAAAGACTTGTTACGAAGAAATGCCCTGGAGTGAATTCTCTCT
 5 TCGTCGATGGCTCCTTCCAGTTACTCTACTTCACTCTGTGCTGGTGGTTGTCTCTG
 CGGCGCTCTACCTGGCTGGGATCGAGGCCTACCTGGCTGTGATGGTCTTTGCCCTGGTC
 CTGGGCTGGATGAATGCGCTGTACTTCACGCGCGGGTTGAAGCTGACGGGGACCTACA
 GCATCATGATTCAGAAGATCCTCTTCAAAGACCTCTTCCGCTTCCTGCTTGTGTACCTG
 CTCTTCATGATCGGCTATGCCTCAGCCCTGGTCACCCTCCTGAATCCGTGCACCAACAT
 10 GAAGGTCTGTGACGAGGACCAGAGCAACTGCACGGTGCCACGTATCCTGCGTGCCGC
 GACAGCGAGACCTTCAGCGCCTTCCTCCTGGACCTCTTCAAGCTCACCATCGGCATGG
 GAGACCTGGAGATGCTGAGCAGCGCCAAGTACCCCGTGGTCTTCATCCTCCTGCTGGT
 CACCTACATCATCCTCACCTTCGTGCTCCTGTTGAACATGCTTATCGCCCTCATGGGTG
 AGACCGTGGGCCAGGTGTCCAAGGAGAGCAAGCACATCTGGAAGTTGCAGTGGGCCA
 15 CCACCATCCTGGACATCGAGCGTTCCTTCCCTGTGTTCCCTGAGGAAGGCCTTCCGCTCC
 GGAGAGATGGTGACTGTGGGCAAGAGCTCAGATGGCACTCCGGACCGCAGGTGGTGC
 TTCAGGGTGGACGAGGTGAACTGGTCTCACTGGAACCAGAACTGGGCATCATTAACG
 AGGACCCTGGCAAGAGTGAAATCTACCAGTACTATGGCTTCTCCCACACCGTGGGGCG
 CCTTCGTAGGGATCGTTGGTCTCGGTGGTGCCCCGCGTAGTGGAGCTGAACAAGAAC
 20 TCAAGCGCAGATGAAGTGGTGGTACCCCTGGATAACCTAGGGAACCCCAACTGTGACG
 GCCACCAGCAGGGCTACGCTCCCAAGTGGAGGACGGACGATGCCCCACTGTAG.

21. Recombinant vector, characterised in that it contains a nucleic acid according to one of claims 1 to 20.
- 25 22. Recombinant vector according to claim 21, characterised in that it is an expression vector.
23. Host, characterised in that it contains a vector according to claim 21 or 22.
24. Host according to claim 23, characterised in that it is a eukaryotic host cell.
25. Host according to claim 23 or 24, characterised in that it is an insect cell.
- 30 26. Host according to one of claims 23 to 25, characterised in that it is an Sf9-, HEK293- or HeLa-cell.
27. Host according to claim 23, characterised in that it is a bacteriophage.
28. Host according to claim 23, characterised in that it is a prokaryotic host cell.
29. Polypeptide, characterised in that it is coded by a nucleic acid according to one of
- 35 claims 1 to 20 or a fragment, a functional variant, an allelic variant, a subunit, a

variant on the basis of the degenerative nucleic acid code, a chemical derivative thereof, a fusion protein with said polypeptide or a glycosylation variant thereof.

30. Polypeptide according to claim 29, characterised in that it is a fragment of the nonselective cation channel OTRPC4.

5 31. Polypeptide according to one of claims 29 and 30, characterised in that it is a functional variant of the nonselective cation channel OTRPC4.

32. Polypeptide according to one of claims 29 to 31, characterised in that it is an allelic variant of the nonselective cation channel OTRPC4.

33. Polypeptide according to one of claims 29 to 32, characterised in that it is a subunit
10 of the nonselective cation channel OTRPC4.

34. Polypeptide according to one of claims 29 to 33, characterised in that it is a variant of the nonselective cation channel OTRPC4 on the basis of the degenerative nucleic acid code.

35. Polypeptide according to one of claims 29 to 34, characterised in that it is a
15 chemical derivative of the nonselective cation channel OTRPC4.

36. Polypeptide according to one of claims 29 to 35, characterised in that it is a fusion protein consisting of the nonselective cation channel OTRPC4 and another protein.

37. Polypeptide according to one of claims 29 to 36, characterised in that it is a glycosylation variant of the nonselective cation channel OTRPC4.

20 38. Process for preparing polypeptides according to one of claims 29 to 37, characterised in that a host according to one of claims 23 to 28 is cultivated and said polypeptide is isolated.

39. Antibody protein, characterised in that it is specific for a polypeptide according to one of claims 29 to 37.

25 40. Process for preparing an antibody protein according to claim 39, characterised in that it comprises the following steps: a host selected from a eukaryotic or prokaryotic cell which contains one or more vectors having one or more nucleic acids specific for the antibody protein, is cultivated under conditions under which said antibody protein is expressed by said host cell and said antibody protein is
30 isolated.

41. Use of a polypeptide according to one of claims 29 to 37 for finding blockers, activators or modulators of said polypeptides.

42. Use of a host according to one of claims 23 to 28 for finding blockers, activators or modulators of OTRPC4 channels.
43. Process for finding blockers, activators or modulators of OTRPC4, characterised in that a host according to one of claims 23 to 28 is incubated with a test substance.
- 5 44. Process according to claim 43, characterised in that a membrane current is measured, said membrane current is compared with a membrane current which is measured in said host after incubation with a known control substance or in the absence of the test substance.
45. Process according to one of claims 43 and 44, characterised in that said blocker is
10 bound to a channel, said host is incubated with a test substance and the displacement of the blocker or activator bound to the channel by the test substance is measured.
46. Process according to one of claims 43 to 45, characterised in that a host according
15 to one of claims 23 to 28 is incubated with a test substance, the intracellular quantity of a divalent cation is determined and said quantity of divalent cation is compared with the quantity of said divalent cation which is measured when said host is incubated with a known control or in the absence of the test substance.
47. Process according to one of claims 43 to 46, characterised in that said process is a
20 high throughput screening (HTS) test or an ultrahigh throughput screening (UHTS) test.
48. Activator of OTRPC4 which can be found using a process according to claims 43 to 47.
49. Blocker of OTRPC4 which can be found using a process according to claims 43 to 47.
- 25 50. Modulator of OTRPC4 which can be found using a process according to claims 43 to 47.
51. Antisense nucleic acid, characterised in that it is capable of hybridising with part of a nucleic acid according to one of claims 1 to 20 under stringent conditions.
52. Antisense nucleic acid according to claim 51, characterised in that it is a ribozyme.
- 30 53. Pharmaceutical composition, characterised in that it contains a nucleic acid according to one of claims 1 to 20 together with pharmaceutically acceptable carriers or excipients.

54. Pharmaceutical composition, characterised in that it contains an antisense nucleic acid according to one of claims 51 to 52 together with pharmaceutically acceptable carriers or excipients .
55. Pharmaceutical composition, characterised in that it contains a polypeptide according to one of claims 29 to 37 together with pharmaceutically acceptable carriers or excipients.
56. Pharmaceutical composition, characterised in that it contains a vector according to one of claims 21 to 22 together with pharmaceutically acceptable carriers or excipients.
57. Pharmaceutical composition, characterised in that it contains a host according to one of claims 23 to 28 together with pharmaceutically acceptable carriers or excipients.
58. Use of a nucleic acid according to one of claims 1 to 20 for preparing a medicament for the treatment of a disease selected from among diabetes, hyperlipidaemia, hyperproteinaemia, hypertension, stroke, renal insufficiency, shock and other pathophysiological conditions characterised by hyper- and hypoosmolarity.
59. Use of an antisense nucleic acid according to one of claims 51 to 52 for preparing a medicament for the treatment of a disease selected from among diabetes, hyperlipidaemia, hyperproteinaemia, hypertension, stroke, renal insufficiency, shock and other pathophysiological conditions characterised by hyper- and hypoosmolarity.
60. Use of a vector according to one of claims 21 to 22 for preparing a medicament for the treatment of a disease selected from among diabetes, hyperlipidaemia, hyperproteinaemia, hypertension, stroke, renal insufficiency, shock and other pathophysiological conditions characterised by hyper- and hypoosmolarity.
61. Use of a host according to one of claims 23 to 28 for preparing a medicament for the treatment of a disease selected from among diabetes, hyperlipidaemia, hyperproteinaemia, hypertension, stroke, renal insufficiency, shock and other pathophysiological conditions characterised by hyper- and hypoosmolarity.
62. Non-human mammal, characterised in that, in addition to its genome, it contains a nucleic acid according to one of claims 1 to 20 (transgene).
63. Non-human mammal, characterised in that, in its genome, a nucleic acid according to one of claims 1 to 20 is inactivated (gene knock-out).

64. Non-human mammal, characterised in that, in its genome, a nucleic acid according to one of claims 1 to 20 is modified (gene knock-in).
65. Process for producing a non-human mammal, characterised in that
- a) embryonic stem cells of said non-human mammal are transfected with a vector which contains a nucleic acid according to one of claims 1 to 20 and permits recombination between the genomic DNA of said non-human mammal and the nucleic acid contained in the vector
 - b) stably transfected stem cells from step a) are isolated and these are transferred into the germline of a female animal of said non-human mammal
 - c) the offspring of said female animal from step b) with a male animal of the same species are analysed for animals which express the polypeptide coded by the nucleic acid from step a).
66. Process for producing a non-human mammal, characterised in that
- d) embryonic stem cells of said non-human mammal are transfected with a vector which contains a nucleic acid which is capable of hybridising with a nucleic acid according to one of claims 1 to 20 under stringent conditions and is inactivated by insertion of an additional nucleic acid sequence and permits recombination between the genomic DNA of said non-human mammal and the nucleic acid contained in the vector
 - e) stably transfected stem cells from step d) are isolated and these are transferred into the germline of a female animal of said non-human mammal
 - f) the offspring of said female animal from step e) with a male animal of the same species are analysed for animals which express the polypeptide coded by the nucleic acid from step d) only slightly or not at all.
67. Process for producing a non-human mammal, characterised in that
- g) embryonic stem cells of said non-human mammal are transfected with a vector which contains a nucleic acid which is capable of hybridising with a nucleic acid according to one of claims 1 to 20 under stringent conditions and is modified by insertion of an additional nucleic acid sequence and permits recombination between the genomic DNA of said non-human mammal and the nucleic acid contained in the vector

- h) stably transfected stem cells from step g) are isolated and these are transferred into the germline of a female animal of said non-human mammal
 - i) the offspring of said female animal from step h) with a male animal of the same species are analysed for animals which express the polypeptide coded by the nucleic acid from step g).
- 5
- 68. Use of a modulator, activator, or inhibitor of OTRPC4 for the regulation of the osmolarity of body fluids.
 - 69. Use according to claim 68, wherein the body fluid is cerebrospinal fluid, intraocular fluid, or saliva.
- 10
- 70. Pharmaceuticall composition comprising a modulator, activator, or inhibitor of OTRPC4, and a pharmaceutically acceptable carrier, excipient, or diluent.